EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Human monoclonal IgG antibodies derived from a patient allergic to birch pollen as tools to study the in situ localization of major birch pollen allergen, Bet v 1, by immunogold electron microscopy






Journal of Allergy & Clinical Immunology 101(1 PART 1): 60-66

Human monoclonal IgG antibodies derived from a patient allergic to birch pollen as tools to study the in situ localization of major birch pollen allergen, Bet v 1, by immunogold electron microscopy

Background: Bet v 1, the major birch pollen allergen, and related allergens present in various tree pollens, fruits, and vegetables represent a family of important cross-reactive allergens. Although the DNA, deduced amino-acid sequence, and structure of Bet v 1 have been determined, little is known regarding its biologic functions. Objective: Human monoclonal antibodies derived from an individual allergic to birch pollen were used for refined ultrastructural localization of Bet v 1 in birch pollen grains to gain information regarding the allergen distribution and its possible biologic function. These data were to be supplemented by sequence analyses. Methods: Ultrathin sections of anhydrously prepared birch pollen grains were incubated with human monoclonal antibodies (BAB1, BAB2, and BAB4). The binding sites were visualized in the transmission electron microscope by gold-conjugated anti-human IgG antibodies. Results: In the cytoplasm of the birch pollen grain, human monoclonal antibodies bound to ribosome-rich areas and to pollen nuclei. Sequence analysis of Bet v 1 and homologous allergens identified a highly conserved p-loop motif in these proteins, which is typically found in nucleotide-binding proteins. Conclusions: Immunolocalization of Bet v 1 to ribosome-rich areas and the nucleus would be consistent with a highly conserved biologic function of Bet v 1 and homologous proteins as nucleotide binding proteins and explains why this group of plant proteins represents highly cross-reactive plant allergens against which many type I patients are sensitized.

(PDF 0-2 workdays service: $29.90)

Accession: 008789274



Related references

Human monoclonal IgG antibodies derived from a patient allergic to birch pollen as tools to study the in situ localization of the major birch pollen allergen, Bet v 1, by immunogold electron microscopy. Journal of Allergy and Clinical Immunology 101(1 Pt 1): 60-66, 1998

Immunogold electron microscopic localization of the cross-reactive two-EF-hand calcium-binding birch pollen allergen Bet v 4 in dry and rehydrated birch pollen. International Archives of Allergy and Immunology 120(4): 287-294, 2000

Immunogold electron microscopy of soluble proteins: localization of Bet v I major allergen in ultra-thin sections of birch pollen after anhydrous fixation techniques. Journal of Histochemistry and Cytochemistry 39(10): 1395-1401, 1991

Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Current Opinion in Investigational Drugs 11(5): 586-596, 2010

The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals. Plos One 10(1): E0117904-E0117904, 2016

Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. International Archives of Allergy and Immunology 138(1): 59-66, 2005

Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. Journal of Allergy and Clinical Immunology 106(1 Pt 1): 101-109, 2000

Recombinant derivatives of the major birch pollen allergen Bet v 1, which induce fewer symptoms and lower mediator release and eosinophil activation than rBet v 1 wild-type in nasal challenges in birch pollen allergic patients. Allergy (Copenhagen) 56(Supplement 68): 94, 2001

Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. FEBS Letters 465(1): 39-46, Jan 7, 2000

Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1. Journal Of Allergy & Clinical Immunology. 99(3): 374-384, 1997